All In Biotech

Drug Trial Radar · NCT01690702

Study of Nab-Paclitaxel in High Risk Early Breast Cancer

Neo-/Adjuvant Phase III Trial to Compare Intense Dose-dense Chemotherapy to Tailored Dose-dense Chemotherapy in Patients With High-risk Early Breast Cancer (GAIN-2)

Last checked: Nov 20, 2026Latest source record: Feb 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,886 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,886

Actual

Start

Sep 2012

Primary completion

Sep 30, 2018

Study completion Jul 20, 2020

Sponsor

Lead sponsor
GBG Forschungs GmbHAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Celgene; Amgen
First posted
Sep 24, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

two-armed trial to compare E-nP-C against tailored dtEC-dtD in patients with high risk early breast cancer

Conditions

  • Breast Cancer

Interventions

  • EpirubicinDrug

  • nab-PaclitaxelDrug

  • CyclophosphamideDrug

  • DocetaxelDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. invasive disease-free survival (IDFS)Time frame: 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Klinikum Frankfurt Höchst

    Frankfurt am Main, Hesse, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.